Overview

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Status:
Not yet recruiting

Trial end date:
2026-11-30

Target enrollment:

Participant gender:

Summary

Clinical study to investigate the efficacy and safety of savolitinib in combination with osimertinib versus platinum-based doublet chemotherapy in participants with EGFR mutated, MET-overexpressed and/or amplified, locally advanced or metastatic NSCLC who have progressed on treatment with Osimertinib.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Carboplatin
Osimertinib
Pemetrexed